On Demand Activities

Up Close and Personalizing Gastric Cancer Care: Precision Medicine with HER2-Targeted Therapies and Other Novel Agents

1.00 hr(s) | CME , MOC , ABIM

Specialty: HER2

Therapeutic Area(s): Oncology

Release Date: July 8, 2020

Expiration Date: July 7, 2021

Location: Internet Activity Enduring

The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer.

Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal & Hematologic Malignancies and Other Cancer Settings

1.00 hr(s) | CME , CPE , MOC , ABIM

Specialty: Cancer

Therapeutic Area(s): Cardiology , Hematology , Oncology

Release Date: July 2, 2020

Expiration Date: July 1, 2021

Location: Internet Activity Enduring

A panel of hematology-oncology experts use the latest guidelines and real-world evidence to explore how the data have influenced clinical decision-making in cancer-associated VTE in different cancer settings. Using clinical scenarios and cases designed to build consensus, the experts illustrate how DOACs can be used to optimally integrate and implement evidence-based strategies for the prevention and treatment of cancer-associated VTE.

Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?

1.00 hr(s) | CME , NCPD , CPE , MOC , ABIM

Specialty: Cancer

Therapeutic Area(s): Hematology , Oncology

Release Date: June 30, 2020

Expiration Date: June 29, 2021

Location: Internet Activity Enduring

In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how this development can lead to clinical improvements in the prevention and management of VTE in the cancer setting.

Unlocking the Benefits of Synergy Between Therapeutic Advances and Holistic Care in Gastric/GEJ Cancers: Current Evidence, Practical Guidance, and Point-of-Care Tools for Implementing a Multidisciplinary Approach to Modern Patient Care

1.50 hr(s) | CME , NCPD , MOC , ABIM

Specialty: Gastric Cancer

Therapeutic Area(s): Oncology

Release Date: June 26, 2020

Expiration Date: June 25, 2021

Location: Internet Activity Enduring

Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as symptom management, psychological support, and nutritional considerations, in addition to effective treatment selection, need to be considered to offer the best clinical and quality of life outcomes to patients. This three-part educational activity offers learners an exclusive look at how science and care merge in the clinic to enhance the multidisciplinary, multidirectional management of patients with gastric/GEJ cancers.

Test Your Knowledge: Current Guidance on GLP-1 Receptor Agonists to Individualize Treatment for T2DM

0.50 hr(s) | CME

Specialty: Diabetes

Therapeutic Area(s): Endocrinology

Release Date: June 25, 2020

Expiration Date: June 24, 2021

Location: Internet Activity Enduring

In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs.

Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team

1.00 hr(s) | CME , MOC , ABIM

Specialty: Lung Cancer

Therapeutic Area(s): Oncology , Thoracic Surgery

Release Date: June 25, 2020

Expiration Date: June 24, 2021

Location: Internet Activity Enduring

The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of further expanding this treatment approach to earlier stages of lung cancer, including as neoadjuvant or adjuvant therapy for patients with resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored, and results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapies in earlier stages of lung cancer remain. For example, which patients are most likely to benefit from immune-based therapies? What is the optimal way to individualize therapy and coordinate care among different specialists, including thoracic surgeons, radiation oncologists, and medical oncologists? How should the various adverse effects associated with these emerging treatment modalities be managed? This educational on-demand activity based on a recent live webcast features expert instruction and practical guidance for how to effectively navigate the rapidly changing and complex immunotherapy landscape in lung cancer, including in earlier disease settings as a component of multimodal therapy. Access the activity to learn more about this timely, important topic, and what the implications are for clinical practice.

Optimizing Precision Medicine in Gastric Cancer Care: Latest and Emerging Evidence on Novel HER2 and Other Molecular Directed Therapies in Gastric Cancer Management

0.50 hr(s) | CME , MOC , ABIM

Specialty: Gastric Cancer

Therapeutic Area(s): Oncology

Release Date: July 25, 2020

Expiration Date: July 24, 2021

Location: Internet Activity Enduring

In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer.

The Pathology-Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

1.00 hr(s) | CME , MOC , ABIM , ABPath , CC

Specialty: Leukemia

Therapeutic Area(s): Oncology , Pathology

Release Date: October 15, 2020

Expiration Date: October 14, 2021

Location: Internet Activity Enduring

In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care.

1 2 3 4 5 12
Copy link
Powered by Social Snap